Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: LKM002
MIFTS: 68

Leukemia

Categories: Blood diseases, Bone diseases, Cancer diseases, Immune diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Leukemia

About this section

MalaCards integrated aliases for Leukemia:

Name: Leukemia 12 74 29 54 42 43 15 37 17 71
Leukemias 15

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Blood diseases Bone diseases Immune diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:1240
ICD9CM 34 208
MeSH 43 D007938
NCIt 49 C3161
SNOMED-CT 67 87163000 93143009
UMLS 71 C0023418
Sources

Summaries for Leukemia

About this section
MedlinePlus : 42 Leukemia is cancer of the white blood cells. White blood cells help your body fight infection. Your blood cells form in your bone marrow. In leukemia, the bone marrow produces abnormal white blood cells. These cells crowd out the healthy blood cells, making it hard for blood to do its work. There are different types of leukemia, including Acute lymphocytic leukemia Acute myeloid leukemia Chronic lymphocytic leukemia Chronic myeloid leukemia Leukemia can develop quickly or slowly. Chronic leukemia grows slowly. In acute leukemia, the cells are very abnormal and their number increases rapidly. Adults can get either type; children with leukemia most often have an acute type. Some leukemias can often be cured. Other types are hard to cure, but you can often control them. Treatments may include chemotherapy, radiation and stem cell transplantation. Even if symptoms disappear, you might need therapy to prevent a relapse. NIH: National Cancer Institute

MalaCards based summary : Leukemia, also known as leukemias, is related to myeloid leukemia and acute leukemia, and has symptoms including edema, chest pain and angina pectoris. An important gene associated with Leukemia is MIR27A (MicroRNA 27a), and among its related pathways/superpathways are NF-kappaB Signaling and Endometrial cancer. The drugs Fosaprepitant and Acitretin have been mentioned in the context of this disorder. Affiliated tissues include myeloid, t cells and b cells, and related phenotypes are Decreased substrate adherent cell growth and Decreased substrate adherent cell growth

Disease Ontology : 12 A cancer that affects the blood or bone marrow characterized by an abnormal proliferation of blood cells.

Wikipedia : 74 Leukemia, also spelled leukaemia, is a group of blood cancers that usually begin in the bone marrow and... more...

Sources

Related Diseases for Leukemia

About this section

Diseases in the Leukemia family:

Chronic Leukemia Acute Leukemia
Subacute Leukemia

Diseases related to Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2741)
# Related Disease Score Top Affiliating Genes
1 myeloid leukemia 35.6 RUNX1 RAF1 NPM1 LIF KIT FLT3
2 acute leukemia 35.4 RUNX1 NPM1 KIT FLT3 ETV6 CEBPA
3 childhood leukemia 35.3 RUNX1 PBX1 ETV6 BCR ABL1
4 chronic myelomonocytic leukemia 35.3 RUNX1 NPM1 KIT FLT3 ETV6
5 leukemia, chronic myeloid 35.2 RUNX1 RAF1 PML NPM1 KIT HOTAIR
6 t-cell acute lymphoblastic leukemia 35.2 RUNX1 FLT3 ETV6 ABL1
7 acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) 35.2 RUNX1 KIT FLT3 ETV6
8 core binding factor acute myeloid leukemia 35.1 RUNX1 KIT FLT3 CEBPA
9 atypical chronic myeloid leukemia 35.1 RUNX1 FLT3 ETV6 ABL1
10 chronic eosinophilic leukemia 35.1 KIT FLT3 ETV6 ABL1
11 acute myeloblastic leukemia with maturation 35.1 NPM1 KIT FLT3
12 cytogenetically normal acute myeloid leukemia 35.0 NPM1 FLT3 CEBPA
13 leukemia, acute lymphoblastic 3 35.0 RUNX1 PBX1 FLT3 ETV6 BCR ABL1
14 childhood acute lymphocytic leukemia 35.0 PBX1 ETV6 ABL1
15 chronic leukemia 35.0 KIT FLT3 BCR ABL1
16 adult acute lymphocytic leukemia 34.9 PBX1 ETV6 ABL1
17 b-cell adult acute lymphocytic leukemia 34.9 PBX1 BCR ABL1
18 acute myeloblastic leukemia without maturation 34.9 NPM1 FLT3
19 childhood acute myeloid leukemia 34.8 NPM1 KIT FLT3
20 precursor t-cell acute lymphoblastic leukemia 34.8 FLT3 ETV6 BCR ABL1
21 b-lymphoblastic leukemia/lymphoma with hyperdiploidy 34.8 PBX1 ETV6 ABL1
22 b-lymphoblastic leukemia/lymphoma with iamp21 34.7 PBX1 ETV6 ABL1
23 b-lymphoblastic leukemia/lymphoma with hypodiploidy 34.7 PBX1 ETV6 CEBPA ABL1
24 cebpa-associated familial acute myeloid leukemia 34.7 RUNX1 NPM1 KIT FLT3 ETV6 CEBPA
25 leukemia, acute lymphoblastic 34.7 RUNX1 PBX1 MIR27A KIT FLT3 ETV6
26 leukemia, chronic lymphocytic 34.5 NPM1 NEAT1 MIR27A KIT FLT3 BCR
27 acute myeloid leukemia with t(8;21)(q22;q22) translocation 34.5 RUNX1 KIT FLT3 CEBPA
28 philadelphia-negative chronic myeloid leukemia 34.3 BCR ABL1
29 testicular leukemia 34.3 ETV6 ABL1
30 myelodysplastic syndrome 34.2 RUNX1 NPM1 KIT FLT3 ETV6 CEBPA
31 8p11 myeloproliferative syndrome 34.1 RUNX1 KIT FLT3 BCR
32 acute promyelocytic leukemia 34.1 RUNX1 PML NPM1 NEAT1 HOTAIRM1 FLT3
33 myeloproliferative neoplasm 34.0 RUNX1 KIT FLT3 ETV6 BCR ABL1
34 myelodysplastic/myeloproliferative neoplasm 33.9 KIT FLT3 ETV6 ABL1
35 polycythemia vera 33.5 KIT FLT3 ETV6 ABL1
36 myeloid sarcoma 33.4 NPM1 KIT FLT3
37 leukemia, acute myeloid 32.9 RUNX1 PML PBX1 NPM1 MIR331 MIR27A
38 myelofibrosis 31.8 RUNX1 NPM1 KIT FLT3 ETV6 CDKN2B-AS1
39 wilms tumor 1 31.8 NPM1 KIT FLT3 CEBPA
40 myeloma, multiple 31.5 MIR331 MIR27A KIT HOTAIR GAS5 FLT3
41 lymphoma, non-hodgkin, familial 31.4 NPM1 MIR331 MIR27A FLT3 ETV6 BCR
42 blood platelet disease 31.4 RUNX1 KIT FLT3
43 hematologic cancer 31.3 RUNX1 NPM1 MIR331 MIR27A KIT FLT3
44 gastrointestinal stromal tumor 31.1 RAF1 KIT HOTAIR FLT3 BCR ABL1
45 aggressive systemic mastocytosis 31.0 RUNX1 KIT FLT3
46 bone marrow cancer 30.6 NPM1 MIR27A KIT FLT3 ABL1
47 cerebellar angioblastoma 30.0 KIT ETV6
48 renal cell carcinoma, nonpapillary 30.0 RAF1 MIR27A KIT HOTAIR GAS5 FLT3
49 cerebral meningioma 29.7 LIFR LIF
50 kidney cancer 29.5 RAF1 MIR27A HOTAIR GAS5

Comorbidity relations with Leukemia via Phenotypic Disease Network (PDN):


Acute Cystitis Deficiency Anemia
Heart Disease Leukemia, Chronic Lymphocytic

Graphical network of the top 20 diseases related to Leukemia:



Diseases related to Leukemia
Sources

Symptoms & Phenotypes for Leukemia

About this section

UMLS symptoms related to Leukemia:


edema, chest pain, angina pectoris

GenomeRNAi Phenotypes related to Leukemia according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased substrate adherent cell growth GR00193-A-1 9.63 KIT
2 Decreased substrate adherent cell growth GR00193-A-2 9.63 ABL1 KIT
3 Decreased substrate adherent cell growth GR00193-A-4 9.63 ABL1 FLT3 KIT
4 Increased HDAC inhibitor resistance GR00115-A-0 8.96 LIF LIFR
5 Increased senescence-associated beta-galactosidase protein expression after pRB stimulation GR00230-A-2 8.32 FLT3

MGI Mouse Phenotypes related to Leukemia:

45 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.3 ABL1 BCR CEBPA ETV6 FLT3 KIT
2 hematopoietic system MP:0005397 10.25 ABL1 BCR CEBPA ETV6 FLT3 KIT
3 growth/size/body region MP:0005378 10.23 ABL1 BCR CEBPA ETV6 FLT3 KIT
4 endocrine/exocrine gland MP:0005379 10.22 ABL1 CEBPA ETV6 FLT3 KIT LIF
5 immune system MP:0005387 10.22 ABL1 BCR CEBPA ETV6 FLT3 KIT
6 embryo MP:0005380 10.15 ABL1 ETV6 KIT LIF LIFR NPM1
7 mortality/aging MP:0010768 10.13 ABL1 BCR CEBPA ETV6 FLT3 KIT
8 liver/biliary system MP:0005370 10.07 ABL1 BCR CEBPA KIT LIF LIFR
9 digestive/alimentary MP:0005381 10.05 ABL1 BCR CEBPA ETV6 KIT LIF
10 neoplasm MP:0002006 9.86 CEBPA ETV6 FLT3 KIT NPM1 PML
11 no phenotypic analysis MP:0003012 9.7 CEBPA ETV6 FLT3 KIT PML RAF1
12 normal MP:0002873 9.61 ABL1 BCR CEBPA ETV6 KIT PBX1
13 respiratory system MP:0005388 9.17 ABL1 CEBPA KIT LIF PBX1 RAF1
Sources

Drugs & Therapeutics for Leukemia

About this section

Drugs for Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 867)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fosaprepitant Approved Phase 4 172673-20-0 219090
2
Acitretin Approved Phase 4 55079-83-9, 69427-46-9 6437841
3
Micafungin Approved, Investigational Phase 4 235114-32-6 477468 3081921
4
Ethanol Approved Phase 4 64-17-5 702
5
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
6
Heparin Approved, Investigational Phase 4 9005-49-6 46507594 772
7
Cefepime Approved, Investigational Phase 4 88040-23-7 5479537
8
Itraconazole Approved, Investigational Phase 4 84625-61-6 55283
9
Valganciclovir Approved, Investigational Phase 4 175865-60-8 64147
10
Methylphenidate Approved, Investigational Phase 4 113-45-1 4158
11
Aprepitant Approved, Investigational Phase 4 170729-80-3 6918365 151165
12
Granisetron Approved, Investigational Phase 4 109889-09-0 3510
13
Palonosetron Approved, Investigational Phase 4 135729-56-5, 119904-90-4 148211
14
Ceftazidime Approved Phase 4 72558-82-8, 78439-06-2 5481173
15
Bupropion Approved Phase 4 34911-55-2, 34841-39-9 444
16
Nitrous oxide Approved, Vet_approved Phase 4 10024-97-2 948
17
Nitric Oxide Approved Phase 4 10102-43-9 145068
18
Penicillin G Approved, Vet_approved Phase 4 61-33-6 5904
19
Tobramycin Approved, Investigational Phase 4 32986-56-4 36294 5496
20
Morphine Approved, Investigational Phase 4 57-27-2 5288826
21
Metformin Approved Phase 4 657-24-9 14219 4091
22
Rasburicase Approved, Investigational Phase 4 134774-45-1
23
Nicotine Approved Phase 4 54-11-5 942 89594
24
Letrozole Approved, Investigational Phase 4 112809-51-5 3902
25
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
26
Prilocaine Approved Phase 4 721-50-6 4906
27
Radium Ra 223 dichloride Approved, Investigational Phase 4 444811-40-9
28
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
29
Ofloxacin Approved Phase 4 82419-36-1 4583
30
Ixazomib Approved, Investigational Phase 4 1072833-77-2
31
Daratumumab Approved Phase 4 945721-28-8
32
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
33
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
34
Ketorolac Approved Phase 4 66635-83-4, 74103-06-3 3826
35
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
36
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
37
Valproic acid Approved, Investigational Phase 4 99-66-1 3121
38
Chlorambucil Approved Phase 4 305-03-3 2708
39
Peginterferon alfa-2b Approved Phase 4 99210-65-8, 215647-85-1
40
Amphotericin B Approved, Investigational Phase 4 1397-89-3 5280965 14956
41
Zidovudine Approved Phase 4 30516-87-1 35370
42
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
43
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 5280795 6221
44
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
45
Calcifediol Approved, Nutraceutical Phase 4 19356-17-3 5283731 6433735
46
Uric acid Investigational Phase 4 69-93-2 1175
47 Antibodies Phase 4
48 Immunoglobulins Phase 4
49 Antibodies, Blocking Phase 4
50
Ethylene Phase 4 74-85-1 6325

Interventional clinical trials:

(show top 50) (show all 7151)
# Name Status NCT ID Phase Drugs
1 Treatment Plan for Hematologic Malignancies Using Intravenous Busulfan and Cyclophosphamide Instead of Total Boby Irradiation (TBI) and Cyclophosphamide to Examine Results, Success and Side Effects of Treatment With Chemotherapy Only, as a Preparative Therapy for Patients With Cord Blood Transplants Unknown status NCT01339988 Phase 4 Busulfan/Cyclophosphamide
2 ASSESSMENT OF GH-IGF1 AXIS AND TO STUDY RESPONSE TO GH THERAPY IN CHILDREN WITH CML IN REMISSION HAVING GH DEFICIENCY Unknown status NCT01901666 Phase 4 Growth Hormone
3 Efficacy and Safety of Imatinib Mesylate as First-line Treatment for the Patients With Chronic Phase of Chronic Myeloid Leukemia Unknown status NCT02317159 Phase 4 Imatinib
4 Multicenter Study To Optimize Treatment in Elderly Patients (> 55 Years, No Upper Age Limit) With Acute Lymphoblastic Leukemia (GMALL Elderly 1/2003)(Amend 2) Unknown status NCT00198978 Phase 4 Cyclophosphamide;Dexamethasone / Prednisolone;Cytarabine;Idarubicin;Granulocyte-Colony-Stimulating Factor;Mercaptopurine;Methotrexate;Rituximab;HDARAC;Vincristine;Depocyte;Asparaginase
5 Low-dose Dasatinib as First-line Treatment for Chronic Myeloid Leukemia Unknown status NCT03216070 Phase 4 Dasatinib 50 MG
6 Multicenter, Phaseâ…£, Open Label Trial of Nilotinib in Adult Patients Diagnosed Philadelphia Chromosome Positive(Ph+) Chronic Myeloid Leukemia in CP/AP Intolerant to Dasatinib Unknown status NCT02389920 Phase 4 Nilotinib
7 A Randomized Comparison of Fludarabine in Combination With Cytarabine Versus High -Dose Cytarabine in Post-remission Therapy for AML1-ETO Acute Myeloid Leukemia Unknown status NCT02024308 Phase 4 Fludarabine;Cytarabine
8 Interferon for the Intervention of Molecular Relapse in t (8; 21) AML After Allo-HSCT Unknown status NCT02027064 Phase 4 Interferon-alpha
9 Philadelphia -Negative High-risk Children Acute Lymphoblastic Leukemia(ALL) Treatment:Induction Therapy:Vincristine(V),Idarubicin(I),L-asparaginase(L),Dexamethasone(D);Consolidation:V+Daunorubicin(D)+L+D, Methotrexate,Cytarabine Unknown status NCT01990807 Phase 4 Idarubicin(IDA)
10 German Multicenter Study for Treatment Optimisation in Acute Lymphoblastic Leukemia in Adults and Adolescents Above 15 Years (Amend 3) (GMALL 07/2003) Unknown status NCT00198991 Phase 4 Cyclophosphamide;Dexamethasone;Vincristine;daunorubicin;Asparaginase;Methotrexate;Cytarabine;Mercaptopurine;G-CSF;Vindesine;VP16;Prednisolone;Adriamycin;Thioguanine;VM26;Idarubicin;Fludarabine;Cladribine
11 AIDA2000 - Risk-Adapted Therapy for Patients With Acute Promyelocytic Leukemia(APL) Unknown status NCT00180128 Phase 4 all-trans retinoid acid;idarubicin;mitoxantrone;daunorubicin;cytarabine
12 A Multicenter, Open-Label Study of Nipent, Cytoxan and Rituxan in Patients With Previously Untreated or Treated Chronic Lymphocytic Leukemia. Unknown status NCT00131313 Phase 4 Nipent, Cytoxan, Rituxan
13 PEG-asparaginase During Two Treatment Courses in the Treatment of Childhood Acute Lymphoblastic Leukemia Unknown status NCT00192673 Phase 4 PEG-asparaginase
14 Multicenter Randomised Clinical Trial in Acute Myeloid Leukemia Treatment Based on Three Anthracyclines, Comparing Two Types of Consolidation With Different ARA-C Doses Followed by One Year Maintenance Unknown status NCT01587430 Phase 4 high dose ARA-C;standard dose ARA-C
15 Decitabine for Myelodysplastic Syndromes and Acute Myeloid Leukemia Before Allogeneic Hematopoietic Cell Transplantation Unknown status NCT01806116 Phase 4 decitabine
16 Optimization of the Primary Therapy for Patients With Hodgkin's Lymphoma and Evaluation of the Positron Emission Tomography (PET) as a Diagnostic Tool for Primary Staging and Assessment of the Effects of the Therapy Unknown status NCT00188149 Phase 4 Combined chemotherapy (ABVD, BACOPP-D)
17 Ma-Spore ALL 2010 Study Unknown status NCT02894645 Phase 4 Prednisolone;Dexamethasone;L-Asparaginase;Vincristine;Methotrexate;Daunorubicin;Doxorubicin;Cyclophosphamide;Cytarabine;6-Mercaptopurine;Thioguanine;Fludarabine;Imatinib
18 Treatment of Elderly Patients (>60 Years) With Acute Myeloblastic Leukemia or Advanced MDS (RAEB-T): An Open Randomized Study to Test the Efficacy of G-CSF-Priming and a Feasibility Trial of Dose-Reduced Allogeneic Transplantation and of Autologous Stem Cell Transplantation Unknown status NCT00199147 Phase 4 Cytarabine;Etoposide;Idarubicin;G-CSF;Fludarabine
19 The Combination of Lower Dosage of Chemotherapy With Tyrosine Kinase Inhibitor to Treat Newly Diagnosed ph+ Acute Lymphoblastic Leukemia Patients Unknown status NCT02690922 Phase 4 Dasatinib;prednisone;dexamethasone;methotrexate
20 Plasma Kinetics of Tablet and Liquid Formulations of 6-mercaptopurine in Childhood Acute Lymphoblastic Leukemia. Unknown status NCT01906671 Phase 4 Xaluprine;Puri-Nethol
21 Medical Research Council Working Party on Leukaemia in Children UK National Acute Lymphoblastic Leukaemia (ALL) Trial: UKALL 2003 Unknown status NCT00222612 Phase 4 Standard childhood UK ALL protocol;Intensified treatment including Capizzi maintenance
22 Clinical Study of GD-2008 ALL Protocol for Childhood Acute Lymphoblastic Leukemia in Guangdong Province Unknown status NCT00846703 Phase 4 6-mercaptopurine, Methotrexate;6-mercaptopurine, Methotrexate, Vincristine, Dexamethasone
23 An Open-label,Multi-center,Prospective Study of Idarubicin and Etoposide Intensified Conditioning Regimen Allogeneic Hematopoietic Stem Cell Transplantation for Adult Acute Lymphoblastic Leukemia Unknown status NCT01873807 Phase 4 IDA;CTX;VP-16
24 Intensification Therapy of Mature B-ALL, Burkitt and Burkitt Like and Other High Grade Non-Hodgkin's Lymphoma in Adults Unknown status NCT00797810 Phase 4 Rituximab
25 A Phase IV, Randomized Study to Evaluate the Safety and Efficacy of Idarubicin at Different Dosages Combined With Cytarabine as Induction Therapy for Newly Diagnosed Acute Myeloid Leukaemia Unknown status NCT02277847 Phase 4 Idarubicin(8mg/m2) and cytosine arabinoside;Idarubicin(10mg/m2), cytosine arabinoside
26 Treatment of Relapsed Acute Promyelocytic Leukemia With Arsenic Trioxide (Phase IV Study) Unknown status NCT00196768 Phase 4 Arsenic trioxide;Trisenox
27 Self-control Trial to Evaluate the Role of Aprepitant in the Prophylaxis of Post-lumbar-punture-headache (PLPH) Unknown status NCT02347878 Phase 4 Aprepitant
28 Evaluation of the Immune Response After Vaccination Against Hepatitis B in Patients With Indolent Lymphoproliferative Disorders With no Treatment. Unknown status NCT01698866 Phase 4
29 Anti-thymocyte Globulins for GVHD Prophylaxis After HLA-matched Sibling Stem Cell Transplantation in Patients at 40 Years of Age or More With Hematological Malignancies Unknown status NCT01856803 Phase 4 anti thymoglobulin
30 An Open Label Trial to Show That Subjects With Severe Plaque-Type Psoriasis Receiving Acitretin 25 mg/Day And Stabilized On A Photochemotherapy Regimen Who Are Experiencing Retinoid-Related Adverse Events, Benefit From A Reduction In Acitretin Dose to 17.5 mg/Day, While Maintaining Comparable Efficacy Along With Improved Tolerability Unknown status NCT01228409 Phase 4 Acitretin 17.5 mg/day
31 A Phase 4, Randomized, Open-Label Study to Assess Humoral and Intestinal Polio Immunity Following a Three-Dose Trivalent Inactivated Polio Vaccine Schedule Relative to Two Sequential Schedules of IPV/Bivalent Oral Polio Vaccines Unknown status NCT01841671 Phase 4
32 1-Year Longitudinal Follow-up Study of Serologic Responses to 7-valent Pneumococcal Conjugated Vaccination and Opsonophagocytic Activities for Streptococcus Pneumoniae Among Patients With Human Immunodeficiency Virus Infection Unknown status NCT00885625 Phase 4
33 An Open-label, Multicenter Study of Treatment With Nilotinib in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Completed NCT00786812 Phase 4 Nilotinib
34 Study Comparing Standard Dose and High-dose Imatinib Mesylate in Patients With Chronic Phase Ph+ CML Completed NCT00171899 Phase 4 imatinib mesylate
35 A Multi-center, Open-label, Exploratory Study of Bcr-Abl Kinetics in Adult Patients on Nilotinib With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) and a Suboptimal Molecular Response to Imatinib Completed NCT00644878 Phase 4 Nilotinib
36 A Phase IV Study of Nilotinib in Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Who Have Suboptimal Molecular Response on Imatinib Completed NCT01043874 Phase 4 Nilotinib
37 Pilot Study for Treatment of Elderly Patients (>65 Years) With Acute Lymphoblastic Leukemia Completed NCT00199095 Phase 4 Adriamycin;Cyclophosphamide;Cytarabine;Dexamethasone;Idarubicin;Ifosfamide;Methotrexate;Mercaptopurine;VM26;Vincristine
38 A Phase IV Study of Corticosteroids As Prophylaxis for Infusion-Related Adverse Events to Mylotarg® in Patients With Acute Myelogenous Leukemia (AML) Completed NCT00304447 Phase 4 Mylotarg
39 A Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib Completed NCT01660906 Phase 4 Dasatinib
40 A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Completed NCT01227577 Phase 4 Nilotinib
41 The Study on the Pharmacokinetics of Pegylated Recombinant Human Granulocyte Stimulating Factor（PEG-rhG-CSF） in Children and Adolescents Completed NCT02953730 Phase 4 PEG-rhG-CSF
42 Multicenter Trial for Treatment of Acute Lymphoblastic Leukemia in Adults (05/93) Completed NCT00199069 Phase 4 Asparaginase;Vincristine;Daunorubicin, Adriamycin;Cyclophosphamide;Ifosfamide;Cytarabine;Mitoxantrone;Methotrexate;6-Mercaptopurine;6-Thioguanine;VM26;Dexamethasone / Prednisolone
43 An Open-label, Multicenter Study of Oral AMN107 (Nilotinib) in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Previously Enrolled to ENACT (CAMN107A2109) Trial Completed NCT01368523 Phase 4 nilotinib
44 Gleevec Trial in Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia Completed NCT00081926 Phase 4 Gleevec
45 A Single-arm, International, Multi-center Trial Investigating the Efficacy and Safety of Ofatumumab Retreatment and Maintenance in CLL Patients Who Progressed Following Response or Stable Disease After Ofatumumab Treatment in Hx-CD20-406 Completed NCT00802737 Phase 4 Ofatumumab
46 A Multicenter Study to Confirm the Efficacy and Safety of Fludara i.v. (Fludarabine Phosphate, SH L 573), Administered in 6 Treatment Cycles (1 Treatment Cycle: 5-consecutive Day Dosing, Followed by an Observation Period of 23 Days) in Untreated Chronic Lymphocytic Leukemia Patients With Anemia and/or Thrombocytopenia Completed NCT00220311 Phase 4 Fludarabine Phosphate (Fludara)
47 A Randomized Open-Label Trial of Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome Completed NCT01200355 Phase 4 micafungin;posaconazole
48 HTLV-I Associated Adult T-cell Leukaemia/Lymphoma (ATLL) Pilot Study of Combination Therapy With CHOP-Zenapax (CHOP-daclizumab) Completed NCT01418430 Phase 4 CHOP-daclizumab
49 Randomised Multicentre Phase IV Study to Compare Glivec® (Imatinib Mesylate, STI571) in Monotherapy Versus Glivec® in Combination With Interferon Alpha at Low Doses in the Treatment of Newly-Diagnosed Chronic-Phase Chronic Myeloid Leukaemia Completed NCT00390897 Phase 4 Glivec;Interferon
50 Pulses of Vincristine and Dexamethasone During Maintenance in BFM Protocols for Children With Intermediate-Risk Acute Lymphoblastic Leukemia Completed NCT00411541 Phase 4 vincristine;dexamethasone

Search NIH Clinical Center for Leukemia

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Cytarabine
Cytarabine liposome
irinotecan
Irinotecan hydrochloride
Isotretinoin
Methotrexate
Methotrexate Sodium
Pipobroman
Vincristine
Vincristine Sulfate

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Leukemia cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Leukemia:
ALD-151, umbilical cord blood cells for hematologic and immunodefeciency diseases
Expanded cord blood hematopoietic stem cells for hematologic malignancies
Hemacord, umbilical cord blood-derived hematopoietic progenitor cells for hematopoietic reconstitution
Embryonic/Adult Cultured Cells Related to Leukemia:
Umbilical cord blood ALDH+ cells (ALD-151) PMIDs: 10430905
Expanded umbilical cord blood-derived hematopoietic stem cells PMIDs: 21396596
Mesenchymal Precursor Cells (STRO-3 selected) PMIDs: 21396596
Umbilical cord blood-derived hematopoietic progenitor cells (HEMACORD) PMIDs: 9828244

Cochrane evidence based reviews: leukemia

Sources

Genetic Tests for Leukemia

About this section

Genetic tests related to Leukemia:

# Genetic test Affiliating Genes
1 Leukemia 29
Sources

Anatomical Context for Leukemia

About this section

MalaCards organs/tissues related to Leukemia:

40
Myeloid, T Cells, B Cells, Bone, Bone Marrow, Monocytes, Testes
Sources

Publications for Leukemia

About this section

Articles related to Leukemia:

(show top 50) (show all 49956)
# Title Authors PMID Year
1
PARP Inhibitors as Therapeutic Options for Tyrosine Kinase-dependent Leukemia: A Review. 42
32487599 2020
2
Entwined lives: the day-to-day of a leukaemia doctor. 42
32220341 2020
3
Oral Health-Related Quality of Life in Adult Patients with Newly Diagnosed Acute Leukaemia. 42
32515417 2020
4
Down-regulated miR-331-5p and miR-27a are associated with chemotherapy resistance and relapse in leukaemia. 46
21070600 2011
5
Activation of Ras-dependent Elk-1 activity by MLL-AF4 family fusion oncoproteins. 61 54
20362031 2010
6
Mcl1 haploinsufficiency protects mice from Myc-induced acute myeloid leukemia. 61 54
20484815 2010
7
Prognostic implications of mutations and expression of the Wilms tumor 1 (WT1) gene in adult acute T-lymphoblastic leukemia. 54 61
20435628 2010
8
Nup98-homeodomain fusions interact with endogenous Nup98 during interphase and localize to kinetochores and chromosome arms during mitosis. 61 54
20237156 2010
9
LLL-3, a STAT3 inhibitor, represses BCR-ABL-positive cell proliferation, activates apoptosis and improves the effects of Imatinib mesylate. 54 61
19701750 2010
10
Expression pattern of the septin gene family in acute myeloid leukemias with and without MLL-SEPT fusion genes. 54 61
19748670 2010
11
Linkage of the potent leukemogenic activity of Meis1 to cell-cycle entry and transcriptional regulation of cyclin D3. 54 61
20237320 2010
12
Wilms' tumor gene 1 protein represses the expression of the tumor suppressor interferon regulatory factor 8 in human hematopoietic progenitors and in leukemic cells. 61 54
20237505 2010
13
Mixed lineage leukemia: a structure-function perspective of the MLL1 protein. 54 61
20236310 2010
14
c-Abl mediates endothelial apoptosis induced by inhibition of integrins alphavbeta3 and alphavbeta5 and by disruption of actin. 54 61
20124512 2010
15
STAT5 in B cell development and leukemia. 54 61
20227268 2010
16
Identification of Zfp521/ZNF521 as a cooperative gene for E2A-HLF to develop acute B-lineage leukemia. 54 61
20062079 2010
17
MLL-rearranged B lymphoblastic leukemias selectively express the immunoregulatory carbohydrate-binding protein galectin-1. 61 54
20332322 2010
18
[Epigenetic mechanism of RUNX1 in pathogenesis of leukemia]. 61 54
20416203 2010
19
MEIS proteins as partners of the TLX1/HOX11 oncoprotein. 54 61
19559479 2010
20
Ordering human CD34+CD10-CD19+ pre/pro-B-cell and CD19- common lymphoid progenitor stages in two pro-B-cell development pathways. 61 54
20231472 2010
21
Functional characterization of high levels of meningioma 1 as collaborating oncogene in acute leukemia. 54 61
20072157 2010
22
Analysis of Ikaros family splicing variants in human hematopoietic lineages. 61 54
20432734 2010
23
The Bcl-2 homology domain 3 mimetic ABT-737 targets the apoptotic machinery in acute lymphoblastic leukemia resulting in synergistic in vitro and in vivo interactions with established drugs. 54 61
20038611 2010
24
KIR2DS3 is associated with protection against acute myeloid leukemia. 61 54
20371915 2010
25
Salicylic acid based small molecule inhibitor for the oncogenic Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2). 54 61
20170098 2010
26
Kinamycin F downregulates cyclin D3 in human leukemia K562 cells. 61 54
20079721 2010
27
Malignant transformation of Slp65-deficient pre-B cells involves disruption of the Arf-Mdm2-p53 tumor suppressor pathway. 54 61
20008789 2010
28
The Lmo2 oncogene initiates leukemia in mice by inducing thymocyte self-renewal. 54 61
20093438 2010
29
Acute T-cell leukemias remain dependent on Notch signaling despite PTEN and INK4A/ARF loss. 61 54
20008304 2010
30
Xenotropic murine leukemia virus-related virus is susceptible to AZT. 54 61
19959199 2010
31
Identification of two critically deleted regions within chromosome segment 7q35-q36 in EVI1 deregulated myeloid leukemia cell lines. 54 61
20084277 2010
32
Up-regulation of survivin by the E2A-HLF chimera is indispensable for the survival of t(17;19)-positive leukemia cells. 61 54
19887369 2010
33
Impact of breast cancer resistance protein on cancer treatment outcomes. 54 61
19949928 2010
34
Estrogen prevents sustained COLO-205 human colon cancer cell growth by inducing apoptosis, decreasing c-myb protein, and decreasing transcription of the anti-apoptotic protein bcl-2. 54 61
20237898 2010
35
Abnormal expression of P2X family receptors in Chinese pediatric acute leukemias. 54 61
19919827 2010
36
Nuclear expression of sox11 is highly associated with mantle cell lymphoma but is independent of t(11;14)(q13;q32) in non-mantle cell B-cell neoplasms. 54 61
19801969 2010
37
[Expression of c-fes gene in leukemia cells and its clinical significance]. 54 61
20030920 2009
38
Contribution of bone microenvironment to leukemogenesis and leukemia progression. 54 61
19727127 2009
39
Epigenetic alterations in a murine model for chronic lymphocytic leukemia. 54 61
19901553 2009
40
E3 ligase-defective Cbl mutants lead to a generalized mastocytosis and myeloproliferative disease. 54 61
19734451 2009
41
The cytotoxic effects of gemtuzumab ozogamicin (mylotarg) in combination with conventional antileukemic agents by isobologram analysis in vitro. 54 61
20032408 2009
42
Genome wide molecular analysis of minimally differentiated acute myeloid leukemia. 61 54
19773259 2009
43
Effects of Manisa propolis on telomerase activity in leukemia cells obtained from the bone marrow of leukemia patients. 54 61
19817639 2009
44
Targeted deletion of p73 in mice reveals its role in T cell development and lymphomagenesis. 61 54
19907659 2009
45
Investigational drugs targeting FLT3 for leukemia. 54 61
19671038 2009
46
On the mechanism of multiple lysine methylation by the human mixed lineage leukemia protein-1 (MLL1) core complex. 54 61
19556245 2009
47
HLA-DRneg patients without acute promyelocytic leukemia show distinct immunophenotypic, genetic, molecular, and cytomorphologic characteristics compared to acute promyelocytic leukemia. 61 54
19291801 2009
48
Induction of hyperproliferative fetal megakaryopoiesis by an N-terminally truncated GATA1 mutant. 61 54
19682090 2009
49
Transformation from committed progenitor to leukemia stem cells. 61 54
19796242 2009
50
Molecular diagnostics of hematologic malignancies. 61 54
19732733 2009